{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:59:49Z","timestamp":1782871189009,"version":"3.54.5"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aim<\/jats:title>\n                  <jats:p>Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for refractory Crohn\u2019s disease [CD]. However, high adverse event rates related to chemotherapy toxicity and immunosuppression limit its applicability. This study aims to evaluate AHSCT\u2019s safety and efficacy using a cyclophosphamide [Cy]-free mobilisation regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective, observational study included 14 refractory CD patients undergoing AHSCT between June 2017 and October 2022. The protocol involved outpatient mobilisation with G-CSF 12\u201316 \u03bcg\/kg\/daily for 5 days, and optional Plerixafor 240 \u03bcg\/d [1\u20132 doses] if the CD34\u2005+\u2005cell count target was unmet. Standard conditioning with Cy and anti-thymocyte globulin was administered. Clinical, endoscopic, and radiological assessments were conducted at baseline and during follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients achieved successful outpatient mobilisation [seven patients needed Plerixafor] and underwent transplantation. Median follow-up was 106 weeks (interquartile range [IQR] 52\u2013348). No mobilisation-related serious adverse events [SAEs] or CD worsening occurred. Clinical and endoscopic remission rates were 71% and 41.7% at 26 weeks, 64% and 25% at 52 weeks, and 71% and 16.7% at the last follow-up, respectively. The percentage of patients who restarted CD therapy for clinical relapse and\/or endoscopic\/radiological activity was 14% at 26 weeks, 57% at 52 weeks, and 86% at the last follow-up, respectively. Peripheral blood cell populations and antibody levels post-AHSCT were comparable to Cy-based mobilisation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cy-free mobilisation is safe and feasible in refractory CD patients undergoing AHSCT. Although relapse occurs in a significant proportion of patients, clinical and endoscopic responses are achieved upon CD-specific therapy reintroduction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae076","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T09:29:11Z","timestamp":1715938151000},"page":"1701-1712","source":"Crossref","is-referenced-by-count":5,"title":["Cyclophosphamide-free Mobilisation Increases Safety While Preserving the Efficacy of Autologous Haematopoietic Stem Cell Transplantation in Refractory Crohn\u2019s Disease Patients"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-2529","authenticated-orcid":false,"given":"Antonio","family":"Giordano","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], University of Barcelona, Josep Carreras Leukaemia Research Foundation , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Veny","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Barastegui","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], University of Barcelona, Josep Carreras Leukaemia Research Foundation , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], University of Barcelona, Josep Carreras Leukaemia Research Foundation , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], University of Barcelona, Josep Carreras Leukaemia Research Foundation , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Su\u00e1rez-Lled\u00f3","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], University of Barcelona, Josep Carreras Leukaemia Research Foundation , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Dom\u00e8nech","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], University of Barcelona, Josep Carreras Leukaemia Research Foundation , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Serrahima","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], University of Barcelona, Josep Carreras Leukaemia Research Foundation , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[{"name":"Apheresis Unit, Department of Hemotherapy and Hemostasis, ICAMS, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Hospital Cl\u00ednic de Barcelona, University of Barcelona , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-4508","authenticated-orcid":false,"given":"Joan","family":"Cid","sequence":"additional","affiliation":[{"name":"Apheresis Unit, Department of Hemotherapy and Hemostasis, ICAMS, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Hospital Cl\u00ednic de Barcelona, University of Barcelona , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Ord\u00e1s","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-0764","authenticated-orcid":false,"given":"Agn\u00e9s","family":"Fern\u00e1ndez-Clotet","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Caballol","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gallego","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Vara","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carme","family":"Masamunt","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0ngel","family":"Giner","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Teubel","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Esteller","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mar\u00eda","family":"Corraliza","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6902","authenticated-orcid":false,"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Salas","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ricart","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department. Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer [IDIBAPS], Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD] , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2024101600034670800_CIT0001","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ecco-jcc\/jjaa173","article-title":"Disease activity patterns of Crohn\u2019s disease in the first 10 years after diagnosis in the population-based IBD South Limburg cohort","volume":"15","author":"Wintjens","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024101600034670800_CIT0002","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/ecco-jcc\/jjab112","article-title":"ECCO topical review: refractory inflammatory bowel disease","volume":"15","author":"Raine","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024101600034670800_CIT0003","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ecco-jcc\/jjx184","article-title":"Autologous haematopoietic stem cell transplantation [AHSCT] in severe Crohn\u2019s disease: a review on behalf of ECCO and EBMT","volume":"12","author":"Snowden","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2024101600034670800_CIT0004","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.3390\/CELLS11213463","article-title":"Hematopoietic stem cell transplantation in refractory Crohn\u2019s disease: should it be considered","volume":"11","author":"Reider","year":"2022","journal-title":"Cells"},{"key":"2024101600034670800_CIT0005","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.2015.16700","article-title":"Autologous hematopoetic stem cell transplantation for refractory Crohn disease a randomized clinical trial","volume":"314","author":"Hawkey","year":"2015","journal-title":"JAMA"},{"key":"2024101600034670800_CIT0006","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ecco-jcc\/jjx180.020","article-title":"Autologous haematopoietic stem cell transplantation for Crohn\u2019s disease: a retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation","volume":"12","author":"Brierley","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2024101600034670800_CIT0007","doi-asserted-by":"crossref","first-page":"e0204914","DOI":"10.1371\/journal.pone.0204914","article-title":"Early and late complications following hematopoietic stem cell transplantation in pediatric patients \u2013 a retrospective analysis over 11 years","volume":"13","author":"Hierlmeier","year":"2018","journal-title":"PLoS One"},{"key":"2024101600034670800_CIT0008","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/j.seminhematol.2007.08.001","article-title":"Autologous stem cell transplantation in autoimmune diseases","volume":"44","author":"Passweg","year":"2007","journal-title":"Semin Hematol"},{"key":"2024101600034670800_CIT0009","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"2024101600034670800_CIT0010","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/gutjnl-2015-309836","article-title":"Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn\u2019s disease","volume":"65","author":"Jauregui-Amezaga","year":"2016","journal-title":"Gut"},{"key":"2024101600034670800_CIT0011","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2468-1253[23]00460-0","article-title":"Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn\u2019s disease [ASTIClite]: an open-label, multicentre, randomised controlled trial","volume":"9","author":"Lindsay","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2024101600034670800_CIT0012","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/ecco-jcc\/jjx054","article-title":"Autologous haematopoietic stem cell transplantation for refractory Crohn\u2019s disease: efficacy in a single-centre cohort","volume":"11","author":"L\u00f3pez-Garc\u00eda","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2024101600034670800_CIT0013","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/ecco-jcc\/jjy203","article-title":"Differences in peripheral and tissue immune cell populations following haematopoietic stem cell transplantation in Crohn\u2019s disease patients","volume":"13","author":"Corraliza","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024101600034670800_CIT0014","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-med-070119-115617","article-title":"Hematopoietic stem cell transplantation for autoimmune disease","volume":"72","author":"Alexander","year":"2021","journal-title":"Annu Rev Med"},{"key":"2024101600034670800_CIT0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2468-1253(24)00004-9","article-title":"Haematopoietic stem-cell transplantation for patients with Crohn\u2019s disease: primum non nocere","volume":"9","author":"Ciccocioppo","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024101600034670800_CIT0016","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.gastro.2004.11.051","article-title":"Autologous hematopoietic stem cell transplantation in patients with refractory Crohn\u2019s disease","volume":"128","author":"Oyama","year":"2005","journal-title":"Gastroenterology"},{"key":"2024101600034670800_CIT0017","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/gut.2007.128694","article-title":"Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn\u2019s disease","volume":"57","author":"Cassinotti","year":"2008","journal-title":"Gut"},{"key":"2024101600034670800_CIT0018","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1182\/blood-2010-06-292391","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up","volume":"116","author":"Burt","year":"2010","journal-title":"Blood"},{"key":"2024101600034670800_CIT0019","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.dld.2011.07.021","article-title":"Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn\u2019s disease","volume":"43","author":"Clerici","year":"2011","journal-title":"Dig Liver Dis"},{"key":"2024101600034670800_CIT0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/apt.12032","article-title":"Remission of refractory Crohn\u2019s disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation","volume":"36","author":"Hasselblatt","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2024101600034670800_CIT0021","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/qjmed\/hcu095","article-title":"Autologous stem cell transplantation in severe treatment-resistant Crohn\u2019s disease: long-term follow-up of UK patients treated on compassionate basis","volume":"107","author":"Snowden","year":"2014","journal-title":"QJM"},{"key":"2024101600034670800_CIT0022","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S2468-1253[17]30056-0","article-title":"Autologous stem-cell transplantation in treatment-refractory Crohn\u2019s disease: an analysis of pooled data from the ASTIC trial","volume":"2","author":"Lindsay","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024101600034670800_CIT0023","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/S13104-017-2824-1","article-title":"Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn\u2019s disease","volume":"10","author":"Ruiz","year":"2017","journal-title":"BMC Res Notes"},{"key":"2024101600034670800_CIT0024","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00520-017-3854-x","article-title":"A systematic literature review of the efficacy, effectiveness, and safety of filgrastim","volume":"26","author":"Dale","year":"2018","journal-title":"Support Care Cancer"},{"key":"2024101600034670800_CIT0025","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study","volume":"51","author":"Afifi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2024101600034670800_CIT0026","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2165\/11206040-000000000-00000","article-title":"Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"2024101600034670800_CIT0027","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.bmt.1703912","article-title":"G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment","volume":"31","author":"Milone","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"2024101600034670800_CIT0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajh.21400","article-title":"Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma","volume":"84","author":"Hosing","year":"2009","journal-title":"Am J Hematol"},{"key":"2024101600034670800_CIT0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1703081","article-title":"Collection of hematopoietic stem cells from patients with autoimmune diseases","volume":"28","author":"Burt","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2024101600034670800_CIT0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.bmt.1701486","article-title":"A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis","volume":"22","author":"Snowden","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"2024101600034670800_CIT0031","doi-asserted-by":"publisher","first-page":"11486","DOI":"10.3748\/wjg.v20.i33.11486","article-title":"Small bowel adenocarcinoma and Crohn\u2019s disease: any further ahead than 50 years ago","volume":"20","author":"Cahill","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024101600034670800_CIT0032","doi-asserted-by":"publisher","first-page":"100097","DOI":"10.1016\/J.CRPHAR.2022.100097","article-title":"Ileal and colonic Crohn\u2019s disease: does location makes a difference in therapy efficacy","volume":"3","author":"Atreya","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2024101600034670800_CIT0033","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736[22]00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2024101600034670800_CIT0034","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736[22]00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae076\/58104212\/jjae076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/10\/1701\/59765739\/jjae076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/10\/1701\/59765739\/jjae076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:03:58Z","timestamp":1729037038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/10\/1701\/7675650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5,17]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae076","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,17]]}}}